ImmuCell Corp Files 8-K on Dec 24 Events
Ticker: ICCC · Form: 8-K · Filed: Dec 29, 2025 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10, $2.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, impairment, disclosure
TL;DR
IMUC filed an 8-K detailing potential material impairments and other events from Dec 24.
AI Summary
ImmuCell Corporation filed an 8-K on December 29, 2025, reporting events that occurred on December 24, 2025. The filing indicates items related to material impairments, other events, and financial statements and exhibits.
Why It Matters
This 8-K filing signals potential material impairments or other significant events that could impact ImmuCell Corporation's financial health and operations.
Risk Assessment
Risk Level: medium — The filing mentions 'Material Impairments,' which could indicate significant negative financial events for the company.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- December 24, 2025 (date) — Earliest event reported
- December 29, 2025 (date) — Filing date
- 56 Evergreen Drive Portland, Maine 04103 (address) — Principal executive offices
FAQ
What specific event triggered the 'Material Impairments' disclosure?
The filing does not specify the exact event that triggered the 'Material Impairments' disclosure, only that it is an item of disclosure for the report dated December 24, 2025.
What are the 'Other Events' being reported by ImmuCell Corporation?
The filing lists 'Other Events' as an item of disclosure but does not provide specific details within the provided text.
When was ImmuCell Corporation incorporated?
ImmuCell Corporation was incorporated in Delaware, as indicated by the filing.
What is ImmuCell Corporation's Standard Industrial Classification (SIC) code?
ImmuCell Corporation's SIC code is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
What is the filing date of this 8-K report?
This 8-K report was filed on December 29, 2025.
Filing Stats: 596 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-12-29 08:00:08
Key Financial Figures
- $0.10 — ge on which registered Common Stock , $0.10 par value per share ICCC The Nasdaq
- $2.3 million — sh impact to profit to be approximately $2.3 million (subject to adjustment pursuant to revi
Filing Documents
- iccc20251224_8k.htm (8-K) — 39KB
- ex_902370.htm (EX-99.1) — 15KB
- 0001437749-25-038773.txt ( ) — 186KB
- iccc-20251224.xsd (EX-101.SCH) — 3KB
- iccc-20251224_def.xml (EX-101.DEF) — 11KB
- iccc-20251224_lab.xml (EX-101.LAB) — 15KB
- iccc-20251224_pre.xml (EX-101.PRE) — 11KB
- iccc20251224_8k_htm.xml (XML) — 3KB
06
Item 2.06 ImmuCell Corporation ("ImmuCell") has announced strategy changes (see Item 8.01 below) that will result in a material charge for a non-cash impairment write-down of certain property, plant and equipment (primarily equipment) during the fourth quarter of 2025. The affected assets are ones relating to the production of Re-Tain . Some but not all of those assets will now be repurposed to manufacture First Defense . ImmuCell presently estimates the non-cash impact to profit to be approximately $2.3 million (subject to adjustment pursuant to review of alternate purposing and net realizable value to be completed as part of the financial closing for the quarter and year ending December 31, 2025). There is no specific cash expenditure related to this write-down.
01
Item 8.01 On December 24, 2025, ImmuCell issued a press release announcing its receipt (on December 23, 2025) of an Incomplete Letter from the United States Food and Drug Administration (FDA) for its Re-Tain New Animal Drug Application (NADA) and announcing ImmuCell's decision to pause further investment in Re-Tain and increase investment in its First Defense franchise.
01. Exhibits
Item 9.01. Exhibits. (d) Exhibits . The following exhibit relating to Item 8.01 shall be deemed to be furnished, and not filed: 99.1 Press Release of the Company dated December 24, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: December 24, 2025 By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of the Company dated December 24, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3